Haya Altawalah

Dr. Haya Altawalah


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
HAHaya Altawalah
Haya Altawalah
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative agent of the ongoing pandemic of coronavirus disease 2019 (COVID-19). The clinical severity of COVID-19 ranges from asymptomatic to critical disease and, eventually, death in smaller subsets of patients. The first case of COVID-19 was declared at the end of 2019 and it has since spread worldwide and remained a challenge in 2021, with the emergence of variants of concern. In fact, new concerns were the still unclear situation of SARS-CoV-2 immunity during the ongoing pandemic and progress with vaccination. If maintained at sufficiently high levels, the immune response could effectively block reinfection, which might confer long-lived protection. Understanding the protective capacity and the duration of humoral immunity during SARS-CoV-2 infection or after vaccination is critical for managing the pandemic and would also provide more evidence about the efficacy of SARS-CoV-2 vaccines. However, the exact features of antibody responses that govern SARS-CoV-2 infection or after vaccination remain unclear. This review summarizes the main knowledge that we have about the humoral immune response during COVID-19 disease or after vaccination. Such knowledge should help to optimize vaccination strategies and public health decisions.

21 November 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
WAWadha Alfouzan
Wadha Alfouzan
FAFaten Al-Wathiqi
Faten Al-Wathiqi
HAHaya Altawalah
Haya Altawalah
Mohammad Assadullah AsadzadehMohammad Assadullah Asadzadeh
Mohammad Assadullah Asadzadeh
ZKZiauddin Khan
Ziauddin Khan
DDDavid W. Denning
David W. Denning
Fungal infections are an increasingly important public health issue, yet accurate statistics on fungal burden worldwide and in Kuwait are scarce. Here we estimate the incidence and prevalence of fungal infections in Kuwait. Population statistics from 2018 collected by the Public Authority for Civil Information were used, as well as data from the Ministry of Health. A literature search for Kuwait data on mycotic diseases and population at risk (chronic obstructive pulmonary disease, HIV infection/AIDS, cancer, and transplant patients) was conducted. The population in 2018 was estimated at 4,226,920 million people: 1,303,246 million Kuwaitis and 2,923,674 million expatriates. We determined the annual burden of serious fungal infections number (per 100,000) from high to low based on earlier reported fungal rates for populations at risk: recurrent Candida vaginitis 54,842 (2595); severe asthma with fungal sensitisation 10,411 (246); allergic bronchopulmonary aspergillosis, 7887 (187); chronic pulmonary aspergillosis 995 (21.3); invasive aspergillosis 704 (16.7); fungal keratitis 654 (15.5); candidaemia 288 (6.8); Candida peritonitis 63 (3.5) and oesophageal candidiasis in HIV 33 (0.8). Besides identifying rising new risk groups and expanding reports on antifungal resistance, surveillance programs and further epidemiological studies are needed to achieve more precise assessments of fungal disease epidemiology and correlated morbidity and mortality.

17 April 2024 in Heliyon
Verified
Journal Article
Open access
HAHaya Altawalah
Haya Altawalah
WAWadha Alfouzan
Wadha Alfouzan
TATalal Al-Fadalah
Talal Al-Fadalah
MZMariam Ali Zalzala
Mariam Ali Zalzala
SESayeh Ezzikouri
Sayeh Ezzikouri
The prevalence of respiratory infections is largely underexplored in Kuwait. The aim of our study is to determine the etiology of infections from patients who are SARS-CoV-2 negative hospitalized with severe lower respiratory tract infections (LRTIs) in Kuwait during the coronavirus disease 2019 (COVID-19) pandemic. We conducted an observational cross-sectional study among severe LRTI patients between September 2021 and March 2022. Respiratory samples from 545 non-COVID-19 severe LRTIs patients were prospectively evaluated with FTD Respiratory 21 Plus® real-time PCR, targeting 20 different viruses and 1 atypical bacterial pathogen. Among all 545 hospitalized cases, 411 (75.4 %) tested positive for at least one respiratory pathogen. The most common were rhinovirus (HRV) (32.7 %), respiratory syncytial virus (RSV) (20.9 %), metapneumovirus (HMPV) (14.1 %), bocavirus (13.2 %), and influenza A (12.7 %). The proportion of pathogens detected was highest in the under-5 age group, while HKU1 (44.4 %) predominated in the elderly (>50 years). Our study reveals a high prevalence of respiratory viruses in severe acute lower respiratory tract infections among non-COVID-19 hospitalized patients in Kuwait. HRV remains the main etiology affecting the country, particularly in infants. These results underscore the necessity of employing multiplex PCR for accurate diagnosis and describing the epidemiology of infections among severe lower respiratory tract infections. This will facilitate the use of specific antiviral therapy and help avoid excessive or inappropriate antibiotic therapy.

2 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
WAWadha Alfouzan
Wadha Alfouzan
HAHaya Altawalah
Haya Altawalah
AAAhmad AlSarraf
Ahmad AlSarraf
WAWalid ALALI
Walid ALALI
TATalal Al-Fadalah
Talal Al-Fadalah
RDRita Dhar
Rita Dhar
We sought to assess pre-vaccination and post-vaccination seroprevalences of anti-SARS-CoV-2 antibodies in Kuwait and to compare antibody levels between vaccine types. In phase 1 (pre-vaccination period, n = 19,363), blood samples were collected before the launch of COVID-19 vaccination in Kuwait between 1 September and 31 December 2020. Blood samples for phase 2 (post-vaccination period, n = 4973) were collected between 1 September and 30 November 2021. We tested subjects for anti-SARS-CoV-2 antibodies using the DiaSorin LIAISON® SARS-CoV-2 IgM and Trimeric S IgG tests. In the pre-vaccination period, the prevalence of SARS-CoV-2 IgM and IgG was 14.50% (95% CI: 14.01–15.00) and 24.89% (95% CI: 24.29–25.50), respectively. The trend of seropositivity increased with age and was higher for females and non-Kuwaiti participants (p < 0.0001). Interestingly, seroprevalence was significantly higher for those who had received one dose of BNT162b2 (95.21%) than those who had received one dose of ChAdOx1-nCov-19 (92.86%). In addition, those who reported receiving two doses had higher seroprevalence, 96.25%, 95.86%, and 94.93% for ChA-dOx1-nCov-19/AstraZeneca, mix-and-match, and BNT162b2 recipients, respectively. After the second dose, median spike-specific responses showed no significant difference between ChAdOx1-nCov-19 and BNT162b2. Furthermore, statistical analysis showed no significant difference between median anti-trimeric S antibody levels of vaccinated individuals according to sex, age, or nationality (p > 0.05). In contrast, a negative correlation between age and anti-trimeric S IgG titers of BNT162b2-vaccinated subjects was observed (r = −0.062, p = 0.0009). Antibody levels decreased with time after vaccination with both vaccines. Our findings indicate that seroprevalence was very low during the pre-vaccination period (25%) in the general population and was greater than 95% in the vaccinated population in Kuwait. Furthermore, ChAdOx1-nCov-19 and BNT162b2 are effective in generating a similar humoral response.

26 August 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
HAHaya Altawalah
Haya Altawalah
FAFarah Altannak
Farah Altannak
KAKarima Abounouh
Karima Abounouh
SESayeh Ezzikouri
Sayeh Ezzikouri
Background: People who inject drugs (PWID) represent a key population disproportionately affected by blood-borne viruses. Updated epidemiological data are crucial for informing public health interventions. This study provides a 2024 update on the seroprevalence and correlates of Hepatitis B (HBV), Hepatitis C (HCV), and Human Immunodeficiency Virus (HIV) among PWID at Kuwait’s national addiction treatment center, building on a previous 2017 baseline. Methods: A cross-sectional study was conducted from January to December 2024, enrolling 1,287 consecutive patients. Serological screening for HBsAg, anti-HCV, and anti-HIV was performed using chemiluminescent immunoassays. Seropositive samples underwent confirmatory nucleic acid testing to detect active viremia. Multivariable logistic regression was used to identify factors associated with each infection. Results: The cohort was predominantly male (86.6%) and Kuwaiti (87.3%), with a median age of 33 years. The overall seroprevalence was 0.2% for HBsAg (2/1,255), 2.1% for anti-HCV (25/1,169), and 0.93% for anti-HIV (12/1,287). A significant age-dependent increase in HCV prevalence was observed ( p < 0.001), with the highest prevalence (10.8%) in participants aged ≥ 50 years. All HIV-positive cases were male. Molecular testing revealed universal active viremia for HCV (100%, 25/25) and HBV (100%, 2/2), and detectable viremia in 66.7% (8/12) of HIV-seropositive cases. In multivariable analysis, increasing age was significantly associated with HCV infection (aOR = 1.1, 95% CI: 1.07–1.16, p < 0.001). For HIV, female sex was associated with significantly lower odds of infection (aOR = 0.14, 95% CI: 0.02–0.92, p = 0.04). Due to the extremely low number of HBV-reactive cases ( n = 2), multivariable logistic regression was not feasible for HBV, and no adjusted estimates could be derived. Conclusion: Compared to 2017 data, this study reveals a concerning increase in HIV prevalence and a shift to universal active HCV viremia among PWID in Kuwait. The near-ubiquitous presence of transmissible infection upon seroconversion indicates a critical gap in the care cascade. These findings underscore an urgent need for the scale-up of targeted harm reduction, test-and-treat strategies, and integrated care services to curb transmission.

4 August 2026 in Hygiene
Verified
Journal Article
Open access
PDF file
AYAnfal Yousef
Anfal Yousef
HAHaya Altawalah
Haya Altawalah
JIJamshaid Iqbal
Jamshaid Iqbal
Background: Toxoplasmosis is a globally prevalent zoonotic infection caused by Toxoplasma gondii, with potentially severe consequences for pregnant women, foetuses, and immunocompromised individuals. Despite its public health importance, epidemiological data on T. gondii infection in Kuwait remain limited and restricted to selected population groups. This study assessed the seroprevalence of T. gondii among community-based adult participants in Kuwait and examined potentially associated risk factors. Methods: A cross-sectional study was conducted in September 2024 in Kuwait City and Jahra governorates. Serum samples from a convenience sample of 200 adults attending governmental polyclinics were screened for T. gondii IgM and IgG antibodies using VIDAS ELISAassays, with IgG-positive samples further analysed for IgG avidity. Demographic and exposure data were collected using structured questionnaires. Univariable and multivariable associations between demographic and exposure-related factors and IgG seropositivity were statistically evaluated. Results: The overall IgG seroprevalence was 11.5% (23/200), with no significant difference between governorates. All samples were IgM-negative, and all IgG-positive and equivocal samples showed high avidity. Age >40 years was associated with seropositivity in univariable analysis, but this association was not significant after adjustment (aOR = 2.21, 95% CI: 0.88–5.89; p = 0.092). No significant associations were observed with sex, nationality, educational level, travel history, cat ownership, or contact with stray cats. Conclusions: Among the participating community-based adults in Kuwait, T. gondii seroprevalence was lower than that reported in several regional studies, with serological findings consistent with past rather than recent infection. No demographic or exposure-related factor was independently associated with seropositivity. Larger population-based studies specifically powered to investigate risk factors and incorporating dietary, occupational, environmental, and migration-related exposures are needed to better characterise transmission pathways and inform targeted One Health surveillance and prevention strategies.